Cargando…
Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole
Gastroesophageal reflux disease is the most common upper gastroenterology disorder in the US. It is associated with a variety of complications and significantly impacts quality of life. Proton pump inhibitors are the most effective treatment. Dexlansoprazole modified release (MR) is a proton pump in...
Autores principales: | Mermelstein, Joseph, Mermelstein, Alanna Chait, Chait, Maxwell M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948703/ https://www.ncbi.nlm.nih.gov/pubmed/27471402 http://dx.doi.org/10.2147/CEG.S91602 |
Ejemplares similares
-
Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions
por: Mermelstein, Joseph, et al.
Publicado: (2018) -
Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor – Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region
por: Goh, Khean Lee, et al.
Publicado: (2016) -
Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease
por: Kukulka, Michael, et al.
Publicado: (2014) -
Complete Resolution of Pseudomalignant Erosion in a Reflux Gastroesophageal Polyp with Proton Pump Inhibitor
por: Nakajima, Takahiko, et al.
Publicado: (2015) -
Dexlansoprazole – a new-generation proton pump inhibitor
por: Skrzydło-Radomańska, Barbara, et al.
Publicado: (2015)